Avidity Biosciences Inc’s filing revealed that its Officer KATHLEEN GALLAGHER acquired Company’s shares for reported $0.18 million on Jun 02 ’25. In the deal valued at $30.98 per share,5,875 shares were bought.
Then, Gallagher Kathleen P. sold 5,875 shares, generating $190,324 in total proceeds. Upon selling the shares at $32.40, the Chief Program Officer now owns 50,554 shares.
Before that, KATHLEEN GALLAGHER bought 5,875 shares. Avidity Biosciences Inc shares valued at $191,819 were divested by the Officer at a price of $32.65 per share.
Citigroup initiated its Avidity Biosciences Inc [RNA] rating to a Buy in a research note published on March 13, 2025; the price target was $70. A number of analysts have revised their coverage, including BMO Capital Markets’s analysts, who began to cover the stock in mid March with a ‘”an Outperform”‘ rating. Scotiabank began covering RNA with “Sector outperform” recommendation on March 07, 2025. H.C. Wainwright started covering the stock on December 20, 2024. It rated RNA as “a Buy”.
Price Performance Review of RNA
On Monday, Avidity Biosciences Inc [NASDAQ:RNA] saw its stock jump 7.07% to $33.17. Over the last five days, the stock has gained 8.47%. Avidity Biosciences Inc shares have risen nearly 14.06% since the year began. Nevertheless, the stocks have risen 24.65% over the past one year. While a 52-week high of $56.00 was reached on 03/13/25, a 52-week low of $21.51 was recorded on 04/09/25. SMA at 50 days reached $29.47, while 200 days put it at $36.10.
Levels Of Support And Resistance For RNA Stock
The 24-hour chart illustrates a support level at 31.63, which if violated will result in even more drops to 30.08. On the upside, there is a resistance level at 33.99. A further resistance level may holdings at 34.80. The Relative Strength Index (RSI) on the 14-day chart is 61.28, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 1.34, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 1.60%. Stochastics %K at 88.20% indicates the stock is a selling.
The most recent change occurred on November 26, 2024 when RBC Capital Mkts began covering the stock and recommended ‘”an Outperform”‘ rating along with a $67 price target.
